Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

PD-1 Success Fuels Interest in Many Immune System Targets

December 28th 2015

It is becoming increasingly clear that PD-1/ PD-L1 and CTLA-4 represent just the tip of the iceberg when it comes to manipulating the immune system to fight cancer, and the number of known checkpoints—and with it the list of potential drug targets—has expanded in recent years.

Importance of BRAF Testing Grows as Options Expand in Melanoma

December 28th 2015

As clinical experience grows with new agents, combinations, and sequences of therapy, the use of molecular profiling in metastatic melanoma is likely to become an essential means of choosing among treatment options.

Pembrolizumab Indication Expanded, EC Approves T-VEC, and More

December 26th 2015

T-VEC Approved in Europe for Unresectable Metastatic Melanoma

December 18th 2015

The European Commission has approved talimogene laherparepvec as a treatment for adult patients with unresectable stage IIIb, IIIc, and IVM1a melanoma that has not spread to the bone, brain, lung, or other viscera.

FDA Approves Two New Indications for Pembrolizumab in Advanced Melanoma

December 18th 2015

The FDA has expanded the approval for single-agent pembrolizumab to include the frontline treatment of patients with advanced melanoma regardless of BRAF status.

Binimetinib Improves PFS in NRAS-Mutant Melanoma

December 16th 2015

The MEK inhibitor binimetinib has demonstrated an improvement in progression-free survival compared with dacarbazine in patients with advanced NRAS-mutant melanoma.

Future Advances in Melanoma Treatment

December 16th 2015

Hot Versus Cold Tumors: Predictive Markers in Melanoma

December 16th 2015

Duration of Dual BRAF-MEK Inhibition in Melanoma

December 16th 2015

Sequencing Dual BRAF-MEK Inhibition and Immunotherapy

December 16th 2015

Treatment of BRAF-Mutant Metastatic Melanoma

December 16th 2015

Combination Immunotherapy Treatment Duration in Melanoma Patients

December 16th 2015

Checkpoint Inhibitors: Combination Therapy in Melanoma

December 16th 2015

Duration of Immunotherapy in Melanoma

December 16th 2015

Sequencing of Checkpoint Agents in Melanoma

December 16th 2015

Use of Immunotherapy Agents in Melanoma Treatment

December 16th 2015

Role of Surgery in the Management of Advanced Melanoma

December 16th 2015

Radiation Therapy and Abscopal Effect in Melanoma Treatment

December 16th 2015

Practical Application of T-VEC in Melanoma Treatment

December 16th 2015

Systemic Therapy with T-VEC in Advanced Melanoma

December 16th 2015

x